1577 related articles for article (PubMed ID: 19695955)
21. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
22. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study.
Chang YJ; Wu DP; Lai YR; Liu QF; Sun YQ; Hu J; Hu Y; Zhou JF; Li J; Wang SQ; Li W; Du X; Lin DJ; Ren HY; Chen FP; Li YH; Zhang X; Huang H; Song YP; Jiang M; Hu JD; Liang YM; Wang JB; Xiao Y; Huang XJ
J Clin Oncol; 2020 Oct; 38(29):3367-3376. PubMed ID: 32650683
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Bertz H; Grishina O; Socié G;
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
[TBL] [Abstract][Full Text] [Related]
24. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
25. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
[TBL] [Abstract][Full Text] [Related]
26. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
[TBL] [Abstract][Full Text] [Related]
27. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
28. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.
Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I
Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046
[TBL] [Abstract][Full Text] [Related]
29. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
30. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
31. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
32. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
33. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
[TBL] [Abstract][Full Text] [Related]
34. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M; Kienast J; Trenschel R; Burchert A; Hegenbart U; Stadler M; Baurmann H; Schäfer-Eckart K; Holler E; Kröger N; Schmid C; Einsele H; Kiehl MG; Hiddemann W; Schwerdtfeger R; Buchholz S; Dreger P; Neubauer A; Berdel WE; Ehninger G; Beelen DW; Schetelig J; Stelljes M
Lancet Oncol; 2012 Oct; 13(10):1035-44. PubMed ID: 22959335
[TBL] [Abstract][Full Text] [Related]
35. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
[TBL] [Abstract][Full Text] [Related]
36. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
37. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation.
Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O
Bone Marrow Transplant; 1999 Oct; 24(8):823-30. PubMed ID: 10516691
[TBL] [Abstract][Full Text] [Related]
38. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
39. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y
J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604
[TBL] [Abstract][Full Text] [Related]
40. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
